

# Proteomic Biomarkers of Heart Failure

Muhammad Zubair Israr, MSc<sup>a,1</sup>, Liam M. Heaney, PhD<sup>a,1</sup>, Toru Suzuki, MD, PhD<sup>a,b,\*</sup>

## KEYWORDS

• Biomarkers • Heart failure • Prognosis • Diagnosis • Proteomics

## KEY POINTS

- Heart failure is associated with significant morbidity and mortality.
- Biomarkers are commonly used for diagnostic and prognostic purposes.
- Protein-based biomarkers have been identified to aid clinicians in the early diagnosis of heart failure and provide added information for prognosis.
- Proteomics is an ever-expanding field that uses techniques to measure a wide range of proteins and peptides in the search to identify potential protein biomarkers.

## INTRODUCTION

It is estimated that in excess of 20,000 protein-coding genes are responsible for the presence of more than 1 million proteins found in biological matrices.<sup>1</sup> The measurement of these proteins, commonly in plasma, serum, urine, saliva, and tissue samples,<sup>2</sup> has provided critical advancements in medical science through the development of diagnostic and prognostic assays for patients presenting with, or at risk of, a multitude of diseases.<sup>3</sup> The use of protein measurements has been particularly beneficial for the assessment of cardiovascular disease, with the notable inclusion of natriuretic peptides and troponin isoforms in clinical decision making for heart failure (HF)<sup>4</sup> and acute coronary syndromes (ACS),<sup>5</sup> respectively. Clinical measurements of endogenous biological substances, such as proteins, lipids, and metabolites, are commonly referred to as biomarkers and provide pathophysiologic information through an associative or direct mechanistic interaction with the diseased system, organ, or tissue.<sup>6</sup> The relationships of protein biomarkers with disease allow

physicians to assess the presence, severity, and/or prognosis of a condition with improved precision and accuracy.<sup>7</sup>

The progression in medical diagnosis and treatment of HF has been heavily influenced by the inclusion of protein biomarker analyses, with measurement of natriuretic peptides commonly used in hospitals worldwide.<sup>8</sup> HF is a major worldwide epidemic associated with high morbidity, mortality, and health care costs affecting more than 23 million people, especially those aged 65 years or older<sup>9</sup>; therefore, any improvements in diagnosis, prognosis, and therapeutic monitoring using protein measurements provide direct improvements in patient care and outcome, as well as economic burden. Difficulties in HF diagnoses exist because of the multifactorial pathophysiology (eg, cardiac stress and injury, neurohormonal activation, and endothelial congestion), and because the signs and symptoms may not arise during early stages of the disease.<sup>10,11</sup> Current guidelines suggest that patients presenting with suspected HF should

Disclosure: The authors have no disclosures.

<sup>a</sup> Department of Cardiovascular Sciences, NIHR Leicester Biomedical Research Centre, University of Leicester, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK; <sup>b</sup> Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken 329-0498, Japan

<sup>1</sup> M.Z. Israr and L.M. Heaney contributed equally to this article.

\* Corresponding author. Department of Cardiovascular Sciences, NIHR Leicester Biomedical Research Centre, University of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK.

E-mail address: [ts263@le.ac.uk](mailto:ts263@le.ac.uk)

Heart Failure Clin ■ (2017) ■–■

<http://dx.doi.org/10.1016/j.hfc.2017.08.010>

1551-7136/17/© 2017 Elsevier Inc. All rights reserved.

be referred for measurement of circulating natriuretic peptides to aid in diagnosis of the condition.<sup>12</sup>

The development and pathophysiology of HF is associated with changes in the expressions of an array of metabolic, signaling, and structural proteins.<sup>13</sup> Although there are several protein-based assays currently used in clinical laboratories, extensive research is being performed to isolate and identify novel protein biomarkers associated with HF in a bid to improve sensitivity and/or specificity of biomarker information. Leading these discovery-led investigations are mass spectrometry (MS)-based assays, which involve a nontargeted approach to protein measurement and come under the remit of proteomics. These assays measure all detectable proteins that are expressed by a cell, tissue, or organism, known as the proteome, and reflect levels present at the time of sample collection.<sup>14,15</sup>

### PROTEOMIC BIOMARKER DISCOVERY

For discovery-led proteomics investigations, the initial phase involves methods using either a wide-span-targeted or nontargeted approach in order to measure a large number of proteins and/or peptides from various biological sample types. This method generates a list of numerous proteins that are identified as associated with the condition being investigated and, therefore, are selected as candidate proteins for subsequent verification experiments. Although many candidate protein biomarkers may be identified through these experimental workflows, very few survive the rigorous validation processes leading to the development of high-throughput assays for measurement.<sup>16</sup> MS is the most widely used instrumentation for nontargeted discovery and identification of potential protein biomarkers. It allows quantitative and qualitative analysis, and peptide sequencing and identification, with great accuracy and sensitivity.<sup>17</sup> Proteomic workflows vary greatly across investigations, including sample preparation, chromatographic gradients, and inclusion of complementary analytical techniques such as ion mobility spectrometry. Furthermore, differences across studies in data processing and statistical testing can lead to misidentification or masking of candidate biomarkers. These widely varied approaches provide limitations in that biomarker identification may not be reproducible across multiple methods, complicating the validation process for novel protein biomarkers. Typically, MS method workflows include fractionation to crudely separate proteins in the sample, removal of highly abundant proteins such as albumin in plasma

samples, further separation of each fraction using liquid chromatography, and MS using electrospray ionization (ESI) in positive ion mode coupled to accurate mass analyzers such as time of flight (ToF) and orbitrap.<sup>18</sup> Alternatively, gel-based approaches are initially used to separate proteins by their isoelectric points and then by mass using polyacrylamide gel (sodium dodecyl sulfate polyacrylamide gel electrophoresis [SDS-PAGE]), followed by staining, excising, digesting using trypsin, and analysis by MS.<sup>19</sup> Following identification of candidate biomarkers, mass spectral data are cross-referenced with large-scale databases to confirm protein identification. Errors in protein quantitation in global discovery techniques can be associated throughout the analytical workflow from sample preparation to analysis. To assist in reducing these errors, isotopic labeling of internal protein standards can allow the relative quantitation of multiple proteins. Examples of these include metabolic labeling (<sup>15</sup>N) and isotope-coded affinity tags; however, they lack accuracy and precision and more reliable approaches for sample-wide quantitation are required.<sup>20</sup>

Traditional nontargeted MS-based methods are important in candidate biomarker identification; however, complex sample preparation and analysis steps create a time-consuming process that limits the throughput required for larger-scale validation studies. Once a list of candidate biomarkers is produced, a shift toward targeted MS approaches allows improved specificity, reproducibility, and quantitation of candidates, and also drastically reduces the analytical run time. A commonly used approach for targeted MS is to develop assays using selective reaction monitoring (SRM) or multiple reaction monitoring (MRM), in which a single ion (SRM) or up to 5 fragment ions (MRM) are monitored in association with a specific product ion, typically using a triple quadrupole MS system, which is able to provide enhanced discriminating power, leading to increased sensitivity, absolute quantitation,<sup>21,22</sup> and improved cross-compatibility between instrumentation.<sup>23</sup> Aside from ESI-MS, matrix-assisted laser desorption ionization (MALDI) ToF-based MS is used for targeted MS, in which proteins of interest can be isolated using immunoprecipitation or liquid chromatography before spotting onto a target plate for analysis. Several targeted protein analyses using MALDI have been reported,<sup>24,25</sup> including an application in clinical studies.<sup>26,27</sup> Before commercialization, targeted protein experiments must replicate the results observed from the nontargeted investigations, as well as expanding to larger sample cohorts including diseased and nondiseased populations to validate as a

biomarker of a condition and to understand normal ranges and potential disease cutoff values.

Because protein expressions show multifaceted temporospatial characteristics driven by responses to physical and/or biological stimuli, there are several complexities involved in the process of identifying a novel protein biomarker. In order to confirm the utility of a candidate biomarker for a clinical purpose, several steps must be achieved, including discovery, qualification, verification, optimization, and validation, followed by commercialization and distribution of assays<sup>28</sup> (Fig. 1). Although the discovery of novel proteins is driven by mass spectrometric methods, validation and commercialization more frequently involve traditional antibody-based techniques such as enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunoblotting, with the less common use of MS-based methods in a clinical setting dictated by obstacles in regulatory approval and cross-site/cross-equipment reproducibility.<sup>29</sup> Regardless of the most suitable analytical method, a successful biomarker must be easily measured, low cost, patient friendly, and show high levels of sensitivity and specificity for its purpose (eg, diagnosis, prognosis).<sup>30</sup>


This article highlights the current clinical uses of protein biomarkers in HF (Fig. 2) and discusses the application of targeted and nontargeted proteomic investigations to discover and develop novel biomarkers centered on using a personalized medicine approach for improved prognostic information.

## MARKERS OF CARDIAC STRESS

### *B-Type Natriuretic Peptide/N-Terminal Pro-B-Type Natriuretic Peptide*

B-type natriuretic peptide (BNP) is perhaps the most widely used biomarker for cardiac stress. It is a central component in cardiovascular homeostasis and is released from the cardiomyocytes, primarily located in the ventricles, in response to stress and stretch of the cardiac muscle.<sup>31</sup> After binding to specific receptors, BNP is activated and drives a reduction in systemic vascular resistance, antagonizes the actions of the renin-angiotensin-aldosterone system, and promotes vasodilation and natriuresis.<sup>32</sup> BNP has been studied extensively for its role as a diagnostic<sup>33–35</sup> and prognostic<sup>36–38</sup> biomarker in HF, including both chronic patients and acute decompensated admissions. However, an important limitation of BNP for HF diagnosis is that circulating levels may become increased in response to alternative disorders such as renal dysfunction, left ventricular hypertrophy, and right ventricular dysfunction.<sup>39</sup> Furthermore, because factors such as sex, age, and body mass index are also associated with fluctuations in BNP levels, accurate interpretation of circulating concentrations is crucial.<sup>40</sup>

In addition to uses in diagnosis and prognosis, BNP has shown utility for the monitoring of patients treated with diuretics and vasodilators such as angiotensin-converting enzyme inhibitors,<sup>41</sup> angiotensin-II receptor antagonists,<sup>42</sup> and aldosterone inhibitors.<sup>43</sup> Circulating BNP levels



**Fig. 1.** Protein biomarker discovery pipeline of novel candidate biomarkers. ELISA, enzyme-linked immune-sorbent assay; LC-MS/MS, liquid chromatography tandem mass spectrometry.

## MARKERS OF NEUROHORMONAL ACTIVATION:


- Copeptin
- Matrix metalloprotease

## MARKERS OF INFLAMMATION OR INJURY:

- Troponin (T and I)
- H-FABP
- CRP
- TNF- $\alpha$
- IL-6

## MARKERS OF CARDIAC STRESS:

- BNP/NTproBNP
- Molecular forms of BNP
- ANP
- ST2
- MRproADM



## MARKERS OF REMODELLING:

- Galectin-3
- GDF-15

## MARKERS OF ASSOCIATED COMORBIDITIES:


## RENAL MARKERS:

- Cystatin C
- NGAL
- PENK



## PULMONARY MARKER:

- Procalcitonin



**Fig. 2.** Protein biomarkers of heart failure and their various pathophysiologic associations. ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CRP, C-reactive protein; GDF-15, growth differentiation factor-15; H-FABP, heart-type fatty acid-binding protein; IL-6, interleukin-6; MRproADM, midregional proadrenomedullin; NGAL, neutrophil gelatinase-associated lipocalin; NTproBNP, N-terminal pro-B-type natriuretic peptide; PENK, proenkephalin; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ .

are known to decrease rapidly following successful treatment strategies, therefore repeat measurements of BNP concentrations provide an observation of responses to medical interventions.

Although widely used in clinical analysis, BNP has a short half-life (approximately 20 minutes) when present in the circulation<sup>44</sup> and, therefore, care must be taken during the sampling and storing of blood samples. N-terminal proBNP (NTproBNP) is released in conjunction with BNP and is considered a more stable alternative because of its longer half-life.<sup>45</sup> NTproBNP is reported to have similar characteristics to BNP as a biomarker for diagnosis,<sup>46–48</sup> prognosis,<sup>42,46,49</sup> and guided treatment<sup>50</sup> in HF.

When studied in direct comparison, BNP and NTproBNP show comparable utility for diagnosis,<sup>42</sup> prognosis,<sup>51,52</sup> and biomarker-guided therapy<sup>53</sup> in chronic HF, with reductions in all-cause mortality reported with titration of therapies based on repeat measurements. Circulating levels of these natriuretic peptide biomarkers are increased in HF and are strongly associated with disease severity and myocardial stretch.<sup>54</sup> Studies, such as the Valsartan Heart Failure Trial

(Val-HeFT), have also shown BNP and NTproBNP to provide superior prognostic information compared with alternative neurohormonal markers of risk.<sup>55</sup>

### **Molecular Forms of B-Type Natriuretic Peptide**

There have been recent research efforts to further understand the degradation pathways of BNP and, with its short half-life in circulation, experiments have also reported the presence of its molecular forms. These molecular forms are truncated BNP peptide chains that are synthesized by the proteolysis of end-chain amino acids and have been identified in the circulation of patients with HF (eg, BNP 3-29, 3-30, 4-29, 5-29), with BNP 3-32, 4-32 and 5-32 reported as the most commonly present.<sup>56</sup> These molecular forms have recently emerged as potential biomarkers for HF, with the major forms previously implicated in ischemic heart disease,<sup>57</sup> which is a major risk factor for development of HF. Furthermore, molecular forms have been reported to associate more closely with clinically measured BNP levels compared with the parent BNP molecule

(BNP 1-32). This finding suggests that the specificity of clinical BNP assays is not unique to BNP 1-32, and that the combination of intact and molecular forms of BNP is a more accurate representation of circulating BNP measurements.<sup>58</sup> More recently, molecular forms of BNP have shown prognostic qualities superior to or comparable with NTproBNP for risk stratification of patients with acute HF. BNP 3-32, 4-32, and notably 5-32 were able to independently predict adverse outcome of patients at 6 months and 1 year, outlining its use as a biomarker to guide outpatient management.<sup>27</sup> However, direct mechanistic actions of these truncated forms, along with the dynamics and kinetics of their degradation pathways, are not currently understood and remain areas of current research.

### ***Atrial Natriuretic Peptide***

---

Atrial natriuretic peptide (ANP) is primarily secreted from the atria and has similar physiological properties to BNP. It is thought to play a role in early HF by preserving the compensated state of left ventricular dysfunction.<sup>59</sup> Although reported to be a prognostic indicator in HF, studies have reported ANP as inferior to BNP primarily because of its decreased stability in circulation and its insensitivity to levels of HF severity.<sup>60,61</sup> Other forms of ANP, such as N-terminal ANP, N-terminal pro-ANP, and midregional pro-ANP (MRproANP), have also been shown to suggest diagnostic and prognostic roles in HF.<sup>61-63</sup> MRproANP has far greater stability in circulation and therefore could prove more suitable for use as a biomarker compared with ANP. An investigation using The Biomarkers in Acute Heart Failure (BACH) cohort reported that MRproANP was a suitable diagnostic and prognostic biomarker in dyspneic patients, with results comparable with those of BNP.<sup>63</sup> Furthermore, additional studies have also indicated that MRproANP provides additive prognostic information to NTproBNP in chronic HF<sup>64</sup> and as a diagnostic marker of acute destabilized HF in patients with dyspnea, again reporting comparable results with the use of both BNP and NTproBNP.<sup>65</sup>

### ***ST2***

---

ST2 is a member of the interleukin (IL)-1 receptor family and has been identified as the target for IL-33, which is expressed under biochemical stress of the heart.<sup>66</sup> ST2 is basally expressed by cardiomyocytes and is detectable in circulation in its soluble form, levels of which are increased in response to mechanical stress of the heart.<sup>67</sup> Its utility has been recognized in HF as an

independent predictor of mortality or need for transplant in patients with severe chronic HF (New York Heart Association [NYHA] class III/IV),<sup>67</sup> as well as providing prognostic information for patients with acute HF when combined with natriuretic peptides,<sup>68</sup> suggesting applicability as a biomarker in combination with current clinical testing strategies (eg, BNP and NTproBNP). Furthermore, although NTproBNP showed improved diagnostic accuracy for patients with acute HF, the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study showed that ST2 was a suitable biomarker to predict 1-year mortality in dyspneic patients, irrespective of a positive or negative diagnosis of acute destabilizing HF,<sup>69</sup> suggesting a more generalized biomarker function that can be further refined when applying a multi-biomarker approach.

### ***Midregional Proadrenomedullin***

---

Adrenomedullin (ADM) is a peptide hormone that has natriuretic, vasodilatory, and hypotensive effects on the heart, with plasma concentrations increased in response to these effects, such as in chronic HF.<sup>70</sup> However, because ADM is unstable in circulation, its midregional prohormone fragment midregional proadrenomedullin (MRproADM) is often measured to perform an indirect quantitation.<sup>71</sup> It has reported a varied role in prognosis, providing information for short-term (30 days) and long-term (4 years) prognosis but less success for midrange predictions of outcome (1 year).<sup>72</sup> MRproADM has also been successfully shown as a prognostic biomarker for patients with acute HF presenting with dyspnea.<sup>73</sup> In this study it was reported as a superior biomarker to both BNP and NTproBNP for the short-term prediction of mortality (90 days) as well as for subsequent patient rehospitalization.<sup>73</sup> Data suggest that it has a suitable role for use in HF prognosis; however, further investigations to confirm its superiority to current biomarkers are warranted.

### **MARKERS OF INFLAMMATION OR INJURY** ***Troponin***

---

Troponin proteins are found in cardiac and skeletal muscle tissue and are involved in the regulation of actin and myosin interactions during muscle contraction. Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) have unique isoforms that exist only in cardiac muscle, allowing the measurement of these specific isoforms to provide information in cardiovascular disease, notably as diagnostic biomarkers for ACS.<sup>74</sup> However, development of high-sensitivity troponin assays have further

allowed the measurement of increased cTnl/cTnT levels in patients with HF,<sup>75,76</sup> with increased concentrations associated with poor outcome. High-sensitivity assays for cTnT have been applied for prognosis in chronic HF, with circulating concentrations able to predict mortality and hospitalization in stabilized patients.<sup>77</sup> Furthermore, cTnT has been shown as a suitable marker to reflect myocardial damage in severe chronic HF,<sup>78</sup> to risk stratify patients on admission for subsequent mortality and morbidity,<sup>79</sup> and to identify patients at high risk of disease deterioration.<sup>80</sup> For acute decompensated HF in the absence of ACS, cTnT is a prognostic marker for short-term and long-term outcomes.<sup>81</sup>

In addition, cTnl has been shown to reflect increased BNP levels, impaired hemodynamics, and worsening of left ventricular dysfunction.<sup>82</sup> For acute admissions, serial changes in cTnl levels over 90 days were functional in predicting increased likelihood of mortality and rehospitalization.<sup>83</sup> When used in combination with BNP measurements, cTnl measurements on admission were shown to predict in-hospital mortality, and increasing concentrations were associated with risk of death in a large-scale registry cohort (the Acute Decompensated Heart Failure National Registry [ADHERE]).<sup>84,85</sup>

### **Heart-Type Fatty Acid-Binding Protein**

Heart-type fatty acid-binding protein (H-FABP) is a small cytosolic protein involved in transporting long-chain fatty acids in the myocardium and is released in response to myocardial damage,<sup>86</sup> indicating its potential as a sensitive biomarker for acute myocardial infarction (MI).<sup>87</sup> H-FABP concentrations are known to be increased in congestive and chronic HF,<sup>88</sup> and are reported to be more sensitive than troponin to detect myocardial damage and identify patients at high risk.<sup>86</sup> Initial investigations have been performed to understand the role and/or association of H-FABP in HF, but further studies are required to assess its utility in comparison with current clinical measurements.

### **C-Reactive Protein**

C-reactive protein (CRP) is a traditional marker of inflammation and high concentrations are commonly associated with mortality in patients with acute MI. However, studies have also shown increased CRP levels in patients with HF, reflecting myocardial damage<sup>89</sup> and associations with HF severity, mortality and morbidity,<sup>90</sup> and rehospitalization.<sup>91</sup> Data indicate that CRP can be used as a predictor for deterioration of heart function;

however, it has also been reported to show no statistical association with left ventricular ejection fraction, providing complications for its suitability and specificity as a biomarker in HF.<sup>92</sup>

### **Tumor Necrosis Factor- $\alpha$**

Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) is a cytokine involved in inflammation and has been reported to be at increased levels in chronic HF.<sup>93</sup> TNF- $\alpha$  has also been implicated in patients with newly diagnosed HF, with increased levels associated with abnormal left atrial dysfunction, and advanced left ventricular diastolic and systolic dysfunction.<sup>94</sup> Further associations have been reported with NYHA class and disease severity,<sup>95</sup> along with the use of TNF- $\alpha$  as a predictor of mortality in advanced HF.<sup>96</sup>

### **Interleukin-6**

IL-6 is also a cytokine involved in inflammation, but it has additional cardiovascular properties through regulation of cardiomyocyte hypertrophy and apoptosis.<sup>97</sup> Cardiac IL-6 expression is reported to increase in advanced HF, suggesting a potential role in prognosis.<sup>98</sup> In addition, increased IL-6 levels have been associated with left ventricular dysfunction before HF diagnosis, highlighting its potential utility as a risk marker for the onset and progression of HF.<sup>99</sup> This prognostic ability has been confirmed in acute HF for prediction of short-term and long-term mortality, both as a sole biomarker and in a multimarker approach when combined with NTproBNP.<sup>100</sup> Furthermore, IL-6, along with CRP and IL-4, concentrations have been shown to increase during a coronary event, returning to preevent levels as symptoms of HF subside over time. This observation indicates a potential role for IL-6 in differentiating between the decompensated and compensated states.<sup>101</sup>

## **MARKERS OF NEUROHORMONAL ACTIVATION**

### **Copeptin**

Preprovasopressin is proteolytically cleaved into copeptin, neurophysin II, and vasopressin, with the vasopressin also known as antidiuretic hormone, which has a prominent role in fluid homeostasis and has been shown to be related to the severity of HF.<sup>102</sup> However, vasopressin is known to show instability in circulation and therefore is troublesome for clinical measurements. In contrast, copeptin is considered to have high stability and is released in equimolar concentrations to vasopressin, allowing a more reliable and

reproducible alternative for indirect measurement of vasopressin.<sup>103</sup> Initial research into the clinical role of copeptin as a prognostic biomarker has suggested it offers superiority over natriuretic peptides for prediction of 14-day and 90-day mortality in acute admissions<sup>73,104</sup> and longer-term prediction at 24 months for patients across various stages of disease,<sup>105</sup> as well as for those with advanced HF.<sup>106</sup> Although a contemporary biomarker for HF, data highlight copeptin measurements as a potential clinical tool for risk stratification, particularly in acute cases.

### **Matrix Metalloproteinases**

Matrix metalloproteinases (MMPs) are a family of zinc-dependent protease enzymes required for normal tissue remodeling and mediating collagen metabolism and extracellular matrix (ECM) homeostasis.<sup>107</sup> Four common classes of MMPs have been identified: gelatinases (MMP-2 and MMP-9), collagenases (MMP-1 and MMP-8), stromelysin (MMP-3), and matrilysin (MMP-7), all of which are regulated by tissue inhibitors.<sup>108</sup>

Increased MMP-9 and MMP-2 concentrations have been reported in patients with HF,<sup>105</sup> with the latter associated with mortality.<sup>109</sup> In contrast, MMP-8 has been shown to have decreased concentrations in patients with chronic HF.<sup>110</sup> Although there are variable alterations of MMPs in patients and more extensive research is required to identify their individual suitability for prognostic investigation, data suggest that they offer additional information when included within a multibiomarker panel.<sup>111</sup> These panel risk scores can improve the information available to identify disease process and HF risk in line with changes to ECM collagen homeostasis and activity of enzymes of remodeling.

### **MARKERS OF REMODELING**

#### ***Galectin-3***

Galectin-3, a member of the lectin family, has been implicated in multiple aspects of HF physiology, including inflammation and ventricular remodeling. It is secreted by activated macrophages that proliferate and cause cardiac fibrosis,<sup>112,113</sup> and has been shown to provide a positive role as a prognostic marker of HF.<sup>114,115</sup> Increased galectin-3 levels have been associated with an increased risk of HF and mortality,<sup>116</sup> with a 2-fold increase in levels associated with a 2-fold increase in risk of death or rehospitalization over an 18-month period.<sup>114</sup> Furthermore, increased concentrations have also been associated with adverse outcome in patients with HF with preserved ejection fraction (HFpEF).<sup>117</sup> As with many proteomic biomarkers of

HF, the role of galectin-3 requires further research, but initial data suggest potential as a marker to stratify patients for HF with or without remodeling.

### ***Growth Differentiation Factor-15***

Growth differentiation factor-15 (GDF-15) is a stress-responsive, transforming growth factor beta-cytokine involved in inflammatory and apoptotic pathways of tissue injury. It is an emerging marker of cardiac dysfunction, and increased levels of GDF-15 have been shown to identify high-risk patients with cardiovascular disease.<sup>118,119</sup> Increased GDF-15 levels have shown mortality prediction in patients with chronic HF, with increased expression of GDF-15 linked to the promotion of protective mechanisms for inhibition of apoptosis, hypertrophy, and adverse remodeling.<sup>120</sup> Increased levels have also been reported to have prognostic utility in patients with both HF with reduced ejection fraction (HFrEF) and HFpEF, adding to current markers such as troponin and NTproBNP.<sup>121,122</sup> For acute decompensated HF, increased GDF-15 concentrations have shown prognostic value for predicting mortality and HF rehospitalization at 1 year, supported by 21 original studies.<sup>123,124</sup>

### **MARKERS OF ASSOCIATED COMORBIDITIES**

#### ***Cystatin C***

Cystatin C is a small protein molecule that is involved in the extracellular inhibition of cathepsins. It is removed from circulation through the kidneys, thus providing biomarker information for renal dysfunction and therefore an interest for cardiovascular disease.<sup>125</sup> Cystatin C has shown prognostic capabilities in patients with chronic HF as well as those with HFpEF.<sup>126-128</sup> These positive relationships with adverse outcome in HF, as well as providing information on dysfunction in the renal system, signify cystatin C as a useful biomarker for a combinatory view of cardiovascular disease and its comorbidities.

#### ***Neutrophil Gelatinase-Associated Lipocalin***

Neutrophil gelatinase-associated lipocalin (NGAL) is an innate antibacterial factor protein of the lipocalin family, initially found to be expressed in neutrophils and later in kidney tubular cells. In kidney dysfunction, NGAL has been shown to be an early marker of injury in animal models and detectable in blood and urine following acute kidney injury.<sup>129,130</sup>

In patients with chronic HF, NGAL concentrations were found to be increased compared with

healthy subjects.<sup>131,132</sup> However, their applicability as a prognostic marker was proved to be inferior to currently established protocols (eg, NTproBNP).<sup>133</sup> In acute cases, the GALLANT (NGAL Evaluation Along with B-type Natriuretic Peptide in acutely Decompensated Heart Failure) trial indicated that NGAL was a strong short-term (30 days) prognostic predictor of HF-related outcomes.<sup>134</sup>

### **Procalcitonin**

Procalcitonin is a precursor peptide of calcitonin and a diagnostic marker of bacterial infections, such as in pneumonia,<sup>135</sup> with increased levels also measured in patients with HF.<sup>136</sup> Increased procalcitonin concentrations were able to predict the risk of long-term death and rehospitalization in acute admissions, irrespective of bacterial infections,<sup>137</sup> and were observed to be in line with disease severity for chronic patients.<sup>138</sup> In addition, serum procalcitonin concentrations provided diagnostic information for HF with high sensitivity and specificity.<sup>139</sup>

### **CONTEMPORARY PROTEOMIC BIOMARKERS**

Recent research has led to an increased number of protein biomarkers that show promise in diagnosis and prognosis of HF conditions. For example, proenkephalin A (PENK) and chromogranin A (CgA) are proteins measured in the circulation that have shown utility as biomarkers in HF, and efforts to validate these for transition into a clinical setting are underway. PENK is a small endogenous opioid peptide that is cleaved to produce enkephalin. Studies have shown that enkephalins are released from nonneuronal tissues, including the kidneys and heart, in response to ischemia.<sup>140</sup> In chronic and acute HF, PENK is associated with glomerular function but does not offer significantly additive prognostic information in addition to current biomarkers of renal function.<sup>141</sup> However, it has provided useful prognostic information for hospitalization or mortality in patients with stable HF.<sup>142</sup> In addition, PENK concentrations have shown predictive capabilities for in-hospital mortality in patients with acute HF, as well as indicating patients at risk of worsening renal function.<sup>143</sup> CgA is a prohormone produced in various tissues, including the heart. Hyperglycosylations of CgA lead to its impaired conversion to catestatin, an action found to be associated with acute HF outcomes.<sup>144</sup> Mixed prognostic quality has been reported in the literature, with studies showing CgA to be associated with the severity of chronic HF and a prognostic marker for mortality,<sup>145</sup> but providing no additive information for

prognosis compared with established protocols and biomarkers.<sup>146</sup> In addition to CgA, chromogranin B, which is colocalized with CgA, has also shown an increase in concentrations to follow the severity and development of HF.<sup>147</sup>

Although PENK and CgA have been taken forward to extended validation studies, discovery-focused proteomics experiments have identified several circulating proteins as potential novel biomarkers for HF. The use of urine sampling as a less-invasive alternative to the traditional blood draw has led to an interest in highlighting urinary proteins for diagnostic testing in HF. Two proteins, insulinlike growth factor-binding protein 2 (IGFBP-2) and orosomucoid 1 (ORM1), have been reported to possess diagnostic potential, providing additive information to current biomarkers such as BNP for IGFBP-2,<sup>148</sup> as well as increasing concentrations in line with the severity of chronic HF and good diagnostic sensitivity (95%) and specificity (85%) for ORM1.<sup>149</sup> These proteins are examples of proteomic biomarkers that have provided initially positive associations, but further validation in extended experiments is required.

Other novel protein discoveries have been supported with initial mechanistic and/or clinical investigations and therefore are following the required pathway for translation into a clinical setting. Leucine-rich  $\alpha$ 2-glycoprotein (LRG) was reported to have an exaggerated expression in patients with a measured BNP of greater than or equal to 100 pg/mL and provided similar diagnostic statistics to BNP.<sup>150</sup> In addition to this, the investigators showed cardiac myocytes to be the origin of LRG release, and more recently it was observed that LRG was active in suppressing adverse remodeling post-MI,<sup>151</sup> and that LRG release in HF may be in response to pressure overload. Calcium-binding proteins A8/9 (S100A8/9) have also been reported to have an upregulated expression as a protective mechanism in HF development, with an observed contribution to the anti-HF effect of hypertrophic preconditioning.<sup>152</sup> In addition to their mechanistic interactions, S100A8/9 have also been shown to provide predictive qualities for mortality in elder patients with severe HF.<sup>153</sup> Similarly, levels of circulating heat shock protein 70 (HSP70) have been shown to increase concurrently with cardiac expression<sup>154</sup> and HF severity,<sup>155</sup> and HSP70 has been implicated as a potential biomarker for early diagnosis of HF.<sup>155</sup>

Although the prior examples of novel biomarkers have undergone initial stages of mechanistic and clinical validation, more recent experiments have indicated further potential biomarkers that remain at the discovery phase. For example, quiescin



Q6 (QSOX1) has shown promise as a biomarker that is specific to acute decompensated HF with dyspnea, with reduced and comparable levels measured in patients with chronic HF and healthy volunteers.<sup>156</sup> QSOX1 has been shown to increase in the left ventricle in an animal HF model<sup>157</sup> and provides diagnostic qualities that are equal to those of BNP and NTproBNP,<sup>156</sup> with increased specificity compared with natriuretic peptides for diagnosis of acute decompensated HF, irrespective of the presence of previous stable HF.

Many candidate proteomic biomarkers for HF have been discovered and are still in the research phase to determine their roles in HF. Limited information regarding their additive role as biomarkers in HF is available and further research for their capacity is required. Extending from single biomarker analyses, proteome-wide investigations have provided insight into multibiomarker models to predict future disease developments. A notable example was presented by Hollander and colleagues,<sup>158</sup> who identified a list of 17 candidate protein biomarkers that, when combined with BNP measurements, were able to provide 97% sensitivity and 100% specificity for classifying patients on recovery from cardiac transplants. This finding provides an opportunity to provide outpatient screening to monitor response to HF treatments but requires extensive additional testing to validate its applicability for everyday clinical use.

## SUMMARY

A wide range of protein-based cardiac biomarkers have shown success in diagnostic and prognostic applications, with several already established as routine measurements in clinical laboratories. Extensive research efforts are currently underway to enhance the current knowledge of protein-cardiovascular disease interactions, led by proteomic-based organizations such as Human Proteome Organization (HUPO). The flagship venture has been The Human Proteome Project (HPP), which is working to map the entire human proteome to further understanding of the localized and systems biology of proteins and protein-protein interactions for diagnostic, prognostic, and therapeutic roles in disease.<sup>2</sup> In particular, HUPO has emphasized the need to develop open-access databases that allow the sharing of proteomics research data across equipment and institutions to detail the human proteome library.<sup>159</sup>

The advancement of technologies, such as MS, that complement traditional enzyme-based assays has allowed the development of highly sensitive and selective methods with the ability to

measure multiple relevant biomarkers in a high-throughput manner. Although at a stage of infancy for translation to functional clinical laboratories, these methods offer the potential for future advancements in the breadth and depth of clinically relevant biomarkers. In addition, the use of multiple omics-based investigatory pathways, including proteomics, metabolomics, lipidomics, and genomics, may lead to the discovery and validation of novel biomarkers that provide improved clinical information to patients in cardiovascular disease and beyond. An example of this approach includes the focus of implementing the combination of protein and metabolite biomarkers to improve risk stratification, with recent demonstration of enhanced prognostic capabilities in chronic and acute HF when combining BNP/NTproBNP with trimethylamine *N*-oxide, a metabolite biomarker linked to gut microbial breakdown of dietary molecules.<sup>160,161</sup> Continued efforts for biomarker discovery and validation promise to unearth novel and contemporary molecules for application in personalized and precision medicine, with the potential to lead to improved prognosis, treatment, and early diagnosis of conditions at the center of public health concerns.

## REFERENCES

1. Jensen ON. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. *Curr Opin Chem Biol* 2004;8:33–41.
2. Legrain P, Aebersold R, Archakov A, et al. The human proteome project: current state and future direction. *Mol Cell Proteomics* 2011;10. M111. 009993.
3. Chan D, Ng LL. Biomarkers in acute myocardial infarction. *BMC Med* 2010;8:34.
4. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002;347:161–7.
5. Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. *Circulation* 1998;98:1853–9.
6. Strimbu K, Tavel JA. What are biomarkers? *Curr Opin HIV AIDS* 2010;5:463.
7. Mayeux R. Biomarkers: potential uses and limitations. *NeuroRx* 2004;1:182–8.
8. Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. *Eur Heart J* 2003;24:1710–8.
9. Roger VL. Epidemiology of heart failure. *Circ Res* 2013;113:646–59.

10. Mentz RJ, O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. *Nat Rev Cardiol* 2016;13:28–35.
11. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. *Nat Rev Cardiol* 2011;8:30–41.
12. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. *Circulation* 2013;128:e240–327.
13. Li W, Rong R, Zhao S, et al. Proteomic analysis of metabolic, cytoskeletal and stress response proteins in human heart failure. *J Cell Mol Med* 2012;16:59–71.
14. James P. Protein identification in the post-genome era: the rapid rise of proteomics. *Q Rev Biophys* 1997;30:279–331.
15. Graves PR, Haystead TA. Molecular biologist's guide to proteomics. *Microbiol Mol Biol Rev* 2002;66:39–63.
16. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery. *Mol Oncol* 2009;3:33–44.
17. Zhou W, Petricoin EF, Longo C. Mass spectrometry-based biomarker discovery. *Methods Mol Biol* 2012;823:251–64.
18. Hathout Y. Proteomic methods for biomarker discovery and validation. Are we there yet? *Expert Rev Proteomics* 2015;12:329–31.
19. Schoenhoff FS, Fu Q, Van Eyk JE. Cardiovascular proteomics: implications for clinical applications. *Clin Lab Med* 2009;29:87–99.
20. Melanson JE, Chisholm KA, Pinto DM. Targeted comparative proteomics by liquid chromatography/matrix-assisted laser desorption/ionization triple-quadrupole mass spectrometry. *Rapid Commun Mass Spectrom* 2006;20:904–10.
21. Carr SA, Abbatiello SE, Ackermann BL, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. *Mol Cell Proteomics* 2014;13:907–17.
22. Pan S, Aebersold R, Chen R, et al. Mass spectrometry based targeted protein quantification: methods and applications. *J Proteome Res* 2008;8:787–97.
23. Mbasu RJ, Heaney LM, Molloy BJ, et al. Advances in quadrupole and time-of-flight mass spectrometry for peptide MRM based translational research analysis. *Proteomics* 2016;16:2206–20.
24. Pan S, Zhang H, Rush J, et al. High throughput proteome screening for biomarker detection. *Mol Cell Proteomics* 2005;4:182–90.
25. Pan S, Rush J, Peskind ER, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. *J Proteome Res* 2008;7:720–30.
26. Reyzer ML, Caprioli RM. MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery. *J Proteome Res* 2005;4:1138–42.
27. Suzuki T, Israr MZ, Heaney LM, et al. Prognostic role of molecular forms of B-type natriuretic peptide in acute heart failure. *Clin Chem* 2017;63:880–6.
28. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. *Nat Biotechnol* 2006;24:971–83.
29. Heaney LM, Jones DJL, Suzuki T. Mass spectrometry in medicine: a technology for the future? *Future Sci OA* 2017;3:FSO213. <http://dx.doi.org/10.4155/fsoa-2017-0053>.
30. Vasan RS. Biomarkers of cardiovascular disease. *Circulation* 2006;113:2335–62.
31. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. *N Engl J Med* 1998;339:321–8.
32. Correa de Sa DD, Chen HH. The role of natriuretic peptides in heart failure. *Curr Heart Fail Rep* 2008;5:177–84.
33. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. *J Am Coll Cardiol* 2001;37:379–85.
34. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. *Lancet* 1997;350:1349–53.
35. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure. *Circulation* 2002;106:416–22.
36. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. *J Am Coll Cardiol* 2007;49:1733–9.
37. Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. *BMJ* 2005;330:625.
38. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. *J Am Coll Cardiol* 2001;37:386–91.
39. Luchner A, Burnett JC Jr, Jougasaki M, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. *J Hypertens* 2000;18:1121–8.
40. Maisel A, Mueller C, Adams K, et al. State of the art: using natriuretic peptide levels in clinical practice. *Eur J Heart Fail* 2008;10:824–39.

41. Felker GM, Hasselblad V, Hernandez AF, et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. *Am Heart J* 2009;158:422–30.
42. Ewald B, Ewald D, Thakkinstian A, et al. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. *Intern Med J* 2008;38:101–13.
43. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. *Eur Heart J* 2006;27:330–7.
44. Potter LR. Natriuretic peptide metabolism, clearance and degradation. *FEBS J* 2011;278:1808–17.
45. Mueller T, Gegenhuber A, Dieplinger B, et al. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. *Clin Chem Lab Med* 2004;42:942–4.
46. Gustafsson F, Steensgaard-Hansen F, Badskjær J, et al. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. *J Card Fail* 2005;11:S15–20.
47. McDonagh TA, Holmer S, Raymond I, et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. *Eur J Heart Fail* 2004;6:269–73.
48. Ozturk TC, Unluer E, Denizbasi A, et al. Can NT-proBNP be used as a criterion for heart failure hospitalization in emergency room? *J Res Med Sci* 2011;16:1564.
49. Taylor CJ, Roalfe AK, Iles R, et al. The potential role of NT-proBNP in screening for and predicting prognosis in heart failure: a survival analysis. *BMJ* 2014;4:e004675.
50. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. *J Am Coll Cardiol* 2009;55:53–60.
51. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. *Eur J Heart Fail* 2004;6:359–63.
52. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. *Eur J Heart Fail* 2004;6:295–300.
53. Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. *BMJ* 2015;350:h910.
54. Kim HN, Januzzi JL. Natriuretic peptide testing in heart failure. *Circulation* 2011;123:2015–9.
55. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Val-sartan Heart Failure (Val-HeFT) data. *Clin Chem* 2006;52:1528–38.
56. Niederkofler EE, Kiernan UA, O'Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. *Circ Heart Fail* 2008;1:258–64.
57. Fujimoto H, Suzuki T, Aizawa K, et al. Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease. *Clin Chem* 2013;59:1330–7.
58. Miller WL, Phelps MA, Wood CM, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. *Circ Heart Fail* 2011;4:355–60.
59. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. *Circulation* 1997;96:509–16.
60. Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. *J Endocrinol Invest* 1998;21:170–9.
61. Luers C, Sutcliffe A, Binder L, et al. NT-proANP and NT-proBNP as prognostic markers in patients with acute decompensated heart failure of different etiologies. *Clin Biochem* 2013;46:1013–9.
62. Lerman A, Gibbons RJ, Rodeheffer RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. *Lancet* 1993;341:1105–9.
63. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. *J Am Coll Cardiol* 2010;55:2062–76.
64. von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. *J Am Coll Cardiol* 2007;50:1973–80.
65. Gegenhuber A, Struck J, Poelz W, et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. *Clin Chem* 2006;52:827–31.

66. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. *J Clin Invest* 2007;117:1538–49.
67. Weinberg EO, Shimp M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. *Circulation* 2003;107:721–6.
68. Rehman SU, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. *J Am Coll Cardiol* 2008;52:1458–65.
69. Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea. *J Am Coll Cardiol* 2007;50:607–13.
70. Jougasaki M, Rodeheffer RJ, Redfield MM, et al. Cardiac secretion of adrenomedullin in human heart failure. *J Clin Invest* 1996;97:2370.
71. Peacock WF. Novel biomarkers in acute heart failure: MR-pro-adrenomedullin. *Clin Chem Lab Med* 2014;52:1433–5.
72. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. *Int J Cardiol* 2013;168:2186–94.
73. Frank Peacock W, Nowak R, Christenson R, et al. Short-term mortality risk in emergency department acute heart failure. *Acad Emerg Med* 2011;18:947–58.
74. Wang TJ. Significance of circulating troponins in heart failure. *Circulation* 2007;116:1217–20.
75. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. *Circulation* 1997;96:2953–8.
76. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. *Am Heart J* 1999;138:95–9.
77. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. *Circulation* 2007;116:1242–9.
78. Setsuta K, Seino Y, Takahashi N, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. *Am J Cardiol* 1999;84:608–11.
79. Ishii J, Cui W, Kitagawa F, et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. *Clin Chem* 2003;49:2020–6.
80. Perna ER, Macin SM, Canella JP, et al. Ongoing myocardial injury in stable severe heart failure. *Circulation* 2004;110:2376–82.
81. Sakhujia R, Green S, Oestreich EM, et al. Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin t for prediction of mortality in acute heart failure. *Clin Chem* 2007;53:412–20.
82. Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. *Circulation* 2003;108:833–8.
83. Xue Y, Clopton P, Peacock WF, et al. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. *Eur J Heart Fail* 2011;13:37–42.
84. Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. *Am J Cardiol* 2008;101:231–7.
85. Peacock WF IV, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. *N Engl J Med* 2008;358:2117–26.
86. Niizeki T, Takeishi Y, Arimoto T, et al. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. *J Card Fail* 2007;13:120–7.
87. Lili C, Xiaomei G, Fei Y. Role of heart-type fatty acid binding protein in early detection of acute myocardial infarction in comparison with cTnI, CK-MB and myoglobin. *J Huazhong Univ Sci Technolog Med Sci* 2004;24:449–51.
88. Arimoto T, Takeishi Y, Shiga R, et al. Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. *J Card Fail* 2005;11:56–60.
89. Berton G, Cordiano R, Palmieri R, et al. C-reactive protein in acute myocardial infarction: association with heart failure. *Am Heart J* 2003;145:1094–101.
90. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure. *Circulation* 2005;112:1428–34.
91. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agata M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. *Eur J Heart Fail* 2002;4:331–6.
92. Oikonomou E, Tousoulis DI, Siasos GE, et al. The role of inflammation in heart failure: new therapeutic approaches. *Hellenic J Cardiol* 2011;52:30–40.
93. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. *N Engl J Med* 1990;323:236–41.
94. Chrysohoou C, Pitsavos C, Barbetseas J, et al. Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). *Heart Vessels* 2009;24:22–6.
95. Rivera M, Taléns-Visconti R, Sirera R, et al. Soluble TNF- $\alpha$  and interleukin-6 receptors in the urine of heart failure patients. Their clinical value and

- relationship with plasma levels. *Eur J Heart Fail* 2004;6:877–82.
96. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure. *Circulation* 2001;103:2055–9.
  97. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. *Heart Fail Rev* 2001;6:95–103.
  98. Gabriele P, Zhi Fang S, Tonny DT, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. *Eur J Heart Fail* 2001;3:415–21.
  99. Raymond RJ, Dehmer GJ, Theoharides TC, et al. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. *Am Heart J* 2001;141:435–8.
  100. Pudil R, Tichý M, Andrys C, et al. Plasma interleukin-6 level is associated with NT-proBNP level and predicts short-and long-term mortality in patients with acute heart failure. *Acta Medica (Hradec Kralove)* 2010;53:225–8.
  101. Sato Y, Takatsu Y, Kataoka K, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. *Clin Cardiol* 1999;22:811–3.
  102. Nakamura T, Funayama H, Yoshimura A, et al. Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. *Int J Cardiol* 2006;106:191–5.
  103. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. *Clin Chem* 2006;52:112–9.
  104. Maisel A, Xue Y, Shah K, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. *Circ Heart Fail* 2011;4:613–20.
  105. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. *J Am Coll Cardiol* 2008;52:266–72.
  106. Stoiser B, Mörtl D, Hülsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. *Eur J Clin Invest* 2006;36:771–8.
  107. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. *Physiol Rev* 2007;87:1285–342.
  108. Yamazaki T, Lee JD, Shimizu H, et al. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. *Eur J Heart Fail* 2004;6:41–5.
  109. George J, Patal S, Wexler D, et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. *Am Heart J* 2005;150:484–7.
  110. Wilson EM, Gunasinghe HR, Coker ML, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. *J Card Fail* 2002;8:390–8.
  111. Zile MR, DeSantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. *Circ Heart Fail* 2011;4:246–56.
  112. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. *Rev Cardiovasc Med* 2010;12:200–10.
  113. Lin YH, Lin LY, Wu YW, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. *Clin Chim Acta* 2009;409:96–9.
  114. Lok DJ, Van Der Meer P, Lipsic E, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. *Clin Res Cardiol* 2010;99:323–8.
  115. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. *Clin Chem* 2012;58:267–73.
  116. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. *J Am Coll Cardiol* 2012;60:1249–56.
  117. Edelmann F, Holzendorf V, Wachter R, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. *Eur J Heart Fail* 2015;17:214–23.
  118. Kempf T, Wollert KC. Growth differentiation factor-15: a new biomarker in cardiovascular disease. *Herz* 2009;34:594–9.
  119. Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. *Curr Heart Fail Rep* 2012;9:337–45.
  120. Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. *J Am Coll Cardiol* 2007;50:1054–60.
  121. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. *Ann Med* 2011;43:60–8.
  122. Chan MM, Santhanakrishnan R, Chong JP, et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. *Eur J Heart Fail* 2016;18:81–8.
  123. Jankovic-Tomasevic R, Pavlovic SU, Jevtovic-Stoimenov T, et al. Prognostic utility of biomarker growth differentiation factor-15 in patients with

- acute decompensated heart failure. *Acta Cardiol* 2016;71:587–95.
124. George M, Jena A, Srivatsan V, et al. GDF 15-A novel biomarker in the offspring for heart failure. *Curr Cardiol Rev* 2016;12:37–46.
  125. Angelidis C, Deftereos S, Giannopoulos G, et al. Cystatin C: an emerging biomarker in cardiovascular disease. *Curr Top Med Chem* 2013;13:164–79.
  126. Huerta A, López B, Ravassa S, et al. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism. *J Hypertens* 2016;34:130–8.
  127. Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. *J Card Fail* 2011;17:31–8.
  128. Nosaka K, Nakamura K, Kusano K, et al. Serum cystatin C as a biomarker of cardiac diastolic dysfunction in patients with cardiac disease and preserved ejection fraction. *Congest Heart Fail* 2013;19:E35–9.
  129. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. *Scand J Clin Lab Invest Suppl* 2008;68:89–94.
  130. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol* 2003;14:2534–43.
  131. Yndestad A, Landrø L, Ueland T, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. *Eur Heart J* 2009;30:1229–36.
  132. Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. *J Card Fail* 2010;16:49–54.
  133. Nymo SH, Ueland T, Askevold ET, et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA. *J Intern Med* 2012;271:436–43.
  134. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL Evaluation Along with B-type Natriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. *Eur J Heart Fail* 2011;13:846–51.
  135. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. *Lancet* 2004;363:600–7.
  136. Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. *Eur J Heart Fail* 2012;14:278–86.
  137. Villanueva MP, Mollar A, Palau P, et al. Procalcitonin and long-term prognosis after an admission for acute heart failure. *Eur J Intern Med* 2015;26:42–8.
  138. Wang W, Zhang X, Ge N, et al. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. *Crit Care* 2014;18:R4.
  139. Canbay A, Celebi OO, Celebi S, et al. Procalcitonin: a marker of heart failure. *Acta Cardiol* 2015;70:473–8.
  140. Denning GM, Ackermann LW, Barna TJ, et al. Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissues. *Peptides* 2008;29:83–92.
  141. Matsue Y, ter Maaten JM, Struck J, et al. Clinical correlates and prognostic value of proenkephalin in acute and chronic heart failure. *J Card Fail* 2017;23:231–9.
  142. Arbit B, Marston N, Shah K, et al. Prognostic usefulness of proenkephalin in stable ambulatory patients with heart failure. *Am J Cardiol* 2016;117:1310–4.
  143. Ng LL, Squire IB, Jones DJ, et al. Proenkephalin, renal dysfunction, and prognosis in patients with acute heart failure: a GREAT network study. *J Am Coll Cardiol* 2017;69:56–69.
  144. Ottesen AH, Carlson CR, Louch WE, et al. Glycosylated chromogranin A in heart failure: implications for processing and cardiomyocyte calcium homeostasis. *Circ Heart Fail* 2017;10:e003675.
  145. Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. *Eur Heart J* 2002;23:967–74.
  146. Røsjø H, Masson S, Latini R, et al. Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial. *Eur J Heart Fail* 2010;12:549–56.
  147. Røsjø H, Husberg C, Dahl MB, et al. Chromogranin B in heart failure: a putative cardiac biomarker expressed in the failing myocardium. *Circ Heart Fail* 2010;3:503–11.
  148. Berry M, Galinier M, Delmas C, et al. Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure. *IJC Metab Endocr* 2015;6:5–12.
  149. Hou LN, Li F, Zeng QC, et al. Excretion of urinary orosomucoid 1 protein is elevated in patients with chronic heart failure. *PLoS One* 2014;9:e107550.
  150. Watson CJ, Ledwidge MT, Phelan D, et al. Proteomic analysis of coronary sinus serum reveals leucine-rich  $\alpha$ 2-glycoprotein as a novel biomarker

- of ventricular dysfunction and heart failure. *Circ Heart Fail* 2011;4:188–97.
151. Kumagai S, Nakayama H, Fujimoto M, et al. Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction. *Cardiovasc Res* 2016;109:272–82.
  152. Wei X, Wu B, Zhao J, et al. Myocardial hypertrophic preconditioning attenuates cardiomyocyte hypertrophy and slows progression to heart failure through upregulation of S100A8/A9. *Circulation* 2015;131:1506–17.
  153. Ma LP, Haugen E, Ikemoto M, et al. S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. *Int J Cardiol* 2012;155:26–32.
  154. Wei YJ, Huang YX, Shen Y, et al. Proteomic analysis reveals significant elevation of heat shock protein 70 in patients with chronic heart failure due to arrhythmogenic right ventricular cardiomyopathy. *Mol Cell Biochem* 2009;332:103–11.
  155. Li Z, Song Y, Xing R, et al. Heat shock protein 70 acts as a potential biomarker for early diagnosis of heart failure. *PLoS One* 2013;8:e67964.
  156. Mebazaa A, Vanpoucke G, Thomas G, et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. *Eur Heart J* 2012;33:2317–24.
  157. Toischer K, Rokita AG, Unsöld B, et al. Differential cardiac remodeling in preload versus afterload. *Circulation* 2010;122:993–1003.
  158. Hollander Z, Lazárová M, Lam KK, et al. Proteomic biomarkers of recovered heart function. *Eur J Heart Fail* 2014;16:551–9.
  159. Orchard S, Hermjakob H, Apweiler R. The proteomics standards initiative. *Proteomics* 2003;3:1374–6.
  160. Tang WW, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure. *J Am Coll Cardiol* 2014;64:1908–14.
  161. Suzuki T, Heaney LM, Bhandari SS, et al. Trimethylamine N-oxide and prognosis in acute heart failure. *Heart* 2016;102:841–8.